Bicycle Therapeutics Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.9%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$2.32next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly559.5MTarget: Sufficient to fund operations into 2030
Quarterly Net Loss Quarterly-60.8MTarget: Reduction in annual operating expenses by approximately 50% through strategic reprioritization
Collaboration Revenue Quarterly900KTarget: Expansion of platform partnerships and radiopharmaceutical collaborations
Watch Items
- Nuzefatide Pevedotin (BT5528) Phase 2 Clinical ProgressTrigger: Enrollment and initial efficacy readouts in recurrent pancreatic ductal adenocarcinoma (PDAC)Action: Monitor clinical trial updates and presentation of Phase 1 combination data with nivolumab
- Workforce Reduction and Operational RestructuringTrigger: Execution of the proposed 30% workforce reduction initiated in March 2026Action: Track realization of the projected 50% reduction in annual operating expenses
- Zelenectide Pevedotin (Duravelo-2) Regulatory AlignmentTrigger: Feedback from FDA, EMA, and MHRA on the randomized Phase 2 trial design and approval pathwayAction: Evaluate strategic options or potential out-licensing/partnership opportunities for the program
Research as of 19 Jun 2026